Innovent Showcases Tri-Specific Autoimmune Therapy Data
SAN FRANCISCO & SUZHOU, China, April 9, 2026 Innovent Biologics, Inc. has unveiled preclinical data for its novel tri-specific...
Innovent Biologics
Advertisement
Innovent Doses First Patient in Phase 3 IBI128 Trial
San Francisco, USA / Suzhou, China | March 22, 2026 Innovent Biologics has announced that the first participant has...
Innovent Secures NMPA Approval for TABOSUN in Colon Cancer
SAN FRANCISCO, U.S. & SUZHOU, China | December 25, 2025 — Innovent Biologics announced that TABOSUN® (ipilimumab N01 injection),...
Innovent Biologics Joins Hang Seng Index, Marking Biopharma Breakthrough
SuZhou, China – Nov. 24, 2025 — Innovent Biologics (01801.HK), a leading Chinese biopharmaceutical company focused on oncology, cardiovascular/metabolic,...
Advertisement
